{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:28:15Z","timestamp":1768037295625,"version":"3.49.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.lpm.2024.104245","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:25:10Z","timestamp":1725632710000},"page":"104245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Duration of anticoagulation of venous thromboembolism"],"prefix":"10.1016","volume":"53","author":[{"given":"Francis","family":"Couturaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meneveau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Emmanuel","family":"Morange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.lpm.2024.104245_bib0001","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/ATVBAHA.114.304488","article-title":"Thrombosis: a major contributor to global disease burden","volume":"34","author":"Raskob","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0002","first-page":"756","article-title":"Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality","volume":"98","author":"Cohen","year":"2007","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0003","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.thromres.2014.07.002","article-title":"Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort","volume":"134","author":"Tagalakis","year":"2014","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.lpm.2024.104245_bib0004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.lpm.2024.104245_bib0005","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"43","key":"10.1016\/j.lpm.2024.104245_bib0006","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1093\/eurheartj\/ehu283","article-title":"2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism","volume":"35","author":"Konstantinides","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lpm.2024.104245_bib0007","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.rmr.2019.05.022","article-title":"Quelle est la dur\u00e9e du traitement anticoagulant pour une EP\/TVP proximale ? [What duration of anticoagulant treatment for PE\/proximal DVT?]","volume":"38","author":"Couturaud","year":"2021","journal-title":"Rev Mal Respir"},{"issue":"1","key":"10.1016\/j.lpm.2024.104245_bib0008","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.rmr.2019.05.038","article-title":"Recommandations de bonne pratique pour la prise en charge de la maladie veineuse thromboembolique chez l'adulte \u2013 Version longue [Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version]","volume":"38","author":"Sanchez","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.lpm.2024.104245_bib0009","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"Rodger","year":"2017","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.lpm.2024.104245_bib0010","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/jth.13781","article-title":"External validation of the DASH prediction rule: a retrospective cohort study","volume":"15","author":"Tosetto","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"14","key":"10.1016\/j.lpm.2024.104245_bib0011","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.lpm.2024.104245_bib0012","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"de Winter","year":"2023","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.lpm.2024.104245_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002883","article-title":"Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: the leiden thrombosis recurrence risk prediction model (L-TRRiP)","volume":"16","author":"Timp","year":"2019","journal-title":"PLoS Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104245_bib0014","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/j.amjmed.2020.03.040","article-title":"Evaluation of venous thromboembolism recurrence scores in an unprovoked pulmonary embolism population: a post-hoc analysis of the PADIS-PE trial","volume":"133","author":"Raj","year":"2020","journal-title":"Am J Med."},{"issue":"8","key":"10.1016\/j.lpm.2024.104245_bib0015","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2024.104245_bib0016","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104245_bib0017","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0140-6736(92)93285-U","article-title":"Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism","volume":"340","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2024.104245_bib0018","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0038-1649783","article-title":"Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis","volume":"74","author":"Levine","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lpm.2024.104245_bib0019","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1056\/NEJM199506223322501","article-title":"A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism","volume":"332","author":"Schulman","year":"1995","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lpm.2024.104245_bib0020","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104245_bib0026","doi-asserted-by":"crossref","first-page":"d3036","DOI":"10.1136\/bmj.d3036","article-title":"Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants\u2019 data from seven trials","volume":"342","author":"Boutitie","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2024.104245_bib0027","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1161\/01.CIR.103.20.2453","article-title":"Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis","volume":"103","author":"Pinede","year":"2001","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.lpm.2024.104245_bib0023","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJM200107193450302","article-title":"Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators","volume":"345","author":"Agnelli","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104245_bib0024","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-139-1-200307010-00008","article-title":"Extended oral anticoagulant therapy after a first episode of pulmonary embolism","volume":"139","author":"Agnelli","year":"2003","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.lpm.2024.104245_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2024.104245_bib0025","doi-asserted-by":"crossref","first-page":"l4363","DOI":"10.1136\/bmj.l4363","article-title":"Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis","volume":"366","author":"Khan","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.lpm.2024.104245_bib0022","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3324\/haematol.2018.210971","article-title":"Six months versus two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial","volume":"104","author":"Couturaud","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.lpm.2024.104245_bib0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bcpt.13625","article-title":"Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk","volume":"129","author":"Johnsen","year":"2021","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.lpm.2024.104245_bib0029","doi-asserted-by":"crossref","first-page":"893","DOI":"10.7326\/0003-4819-139-11-200312020-00007","article-title":"Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis","volume":"139","author":"Linkins","year":"2003","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.lpm.2024.104245_bib0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med."},{"issue":"26","key":"10.1016\/j.lpm.2024.104245_bib0031","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0032","first-page":"834","article-title":"Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism","volume":"110","author":"Lecumberri","year":"2013","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.lpm.2024.104245_bib0033","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.7326\/M21-1094","article-title":"Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis","volume":"174","author":"Khan","year":"2021","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.lpm.2024.104245_bib0034","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.lpm.2024.104245_bib0036","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/jth.15661","article-title":"Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: systematic review and meta-analysis","volume":"20","author":"Wiegers","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0037","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jth.15639","article-title":"Risk factors for recurrence during a pregnancy following a first venous thromboembolism: a French observational study","volume":"20","author":"de Moreuil","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.lpm.2024.104245_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03002-2021","article-title":"Risk stratification for predicting recurrent venous thromboembolism after discontinuation of anticoagulation: a post hoc analysis of a French prospective multicentre study","volume":"60","author":"Le Mao","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0039","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.rmr.2021.03.001","article-title":"Traitement de la maladie veineuse thromboembolique au cours du cancer. Mise \u00e0 jour mars 2021 [Treatment of cancer associated thrombosis. 2019 update of the French guidelines]","volume":"38","author":"Mah\u00e9","year":"2021","journal-title":"Rev Mal Respir"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.revmed.2024.04.004","article-title":"Traduction et republication de: \u00ab Traitement anticoagulant de la maladie veineuse thromboembolique associ\u00e9e au cancer \u00bb [Translation into French and republication of: \"Anticoagulant treatment of cancer-associated thromboembolism\"]","volume":"45","author":"Mah\u00e9","year":"2024","journal-title":"Rev Med Interne."},{"key":"10.1016\/j.lpm.2024.104245_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102194","article-title":"The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis","volume":"64","author":"van Hylckama Vlieg","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"21","key":"10.1016\/j.lpm.2024.104245_bib0042","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMra1705454","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"378","author":"Garcia","year":"2018","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.lpm.2024.104245_bib0035","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2014-03-559757","article-title":"Factors that predict thrombosis in relatives of patients with venous thromboembolism","volume":"124","author":"Couturaud","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.lpm.2024.104245_bib0043","doi-asserted-by":"crossref","first-page":"578","DOI":"10.7326\/0003-4819-152-9-201005040-00008","article-title":"Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism","volume":"152","author":"Carrier","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2024.104245_bib0044","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jama.279.6.458","article-title":"Risk of fatal pulmonary embolism in patients with treated venous thromboembolism","volume":"279","author":"Douketis","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.lpm.2024.104245_bib0045","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.14477","article-title":"Risk of recurrent venous thromboembolism after acute pulmonary embolism: role of residual pulmonary obstruction and persistent right ventricular dysfunction. A meta-analysis","volume":"17","author":"Becattini","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.lpm.2024.104245_bib0046","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1182\/blood-2008-06-163279","article-title":"Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial","volume":"112","author":"Kearon","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.lpm.2024.104245_bib0047","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/jama.2009.853","article-title":"Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review","volume":"301","author":"Segal","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.lpm.2024.104245_bib0048","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.thromres.2015.03.010","article-title":"Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies","volume":"135","author":"Di Minno","year":"2015","journal-title":"Thromb Research"},{"key":"10.1016\/j.lpm.2024.104245_bib0049","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1056\/NEJMoa054444","article-title":"D-dimer testing to determine the duration of anticoagulation therapy","volume":"355","author":"Palareti","year":"2006","journal-title":"NEJM"},{"issue":"1","key":"10.1016\/j.lpm.2024.104245_bib0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.7326\/M14-1275","article-title":"D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study","volume":"162","author":"Kearon","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.lpm.2024.104245_bib0051","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2009-04-215418","article-title":"A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families","volume":"114","author":"Lijfering","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.lpm.2024.104245_bib0052","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01202-2017","article-title":"Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial","volume":"51","author":"Tromeur","year":"2018","journal-title":"Eur Respir J."},{"issue":"11","key":"10.1016\/j.lpm.2024.104245_bib0053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142070","article-title":"A qualitative study to appraise patients and family members perceptions, knowledge, and attitudes towards venous thromboembolism risk","volume":"10","author":"Haxaire","year":"2015","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.lpm.2024.104245_bib0054","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJM199802123380701","article-title":"A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Pr\u00e9vention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group","volume":"338","author":"Decousus","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2024.104245_bib0055","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"issue":"21","key":"10.1016\/j.lpm.2024.104245_bib0056","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lpm.2024.104245_bib0057","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.lpm.2024.104245_bib0058","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa035422","article-title":"Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism","volume":"349","author":"Kearon","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2024.104245_bib0059","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078676","article-title":"Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial","volume":"14","author":"Burggraaf-van Delft","year":"2024","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.lpm.2024.104245_bib0060","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2015.02.001","article-title":"Duration of anticoagulation after venous thromboembolism in real world clinical practice","volume":"135","author":"Ageno","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.lpm.2024.104245_bib0061","doi-asserted-by":"crossref","first-page":"c5146","DOI":"10.1136\/bmj.c5146","article-title":"Implementing shared decision making in the NHS","volume":"341","author":"Elwyn","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.lpm.2024.104245_bib0062","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2147\/VHRM.S331614","article-title":"Factor XI inhibition for the prevention of venous thromboembolism: an update on current evidence and future perspectives","volume":"18","author":"Poenou","year":"2022","journal-title":"Vasc Health Risk Manag"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T01:46:55Z","timestamp":1737596815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0755498224000241"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104245","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duration of anticoagulation of venous thromboembolism","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104245"}}